TOS-358 Single Agent Arm for Squamous Cell Carcinoma

START- Mountain Region, West Valley City, UT
Squamous Cell Carcinoma+34 More ConditionsTOS-358 - Drug
Eligibility
18+
All Sexes

Study Summary

This trial tests how safe and tolerable a new cancer treatment is for adults with certain types of tumors.

Eligible Conditions
  • Squamous Cell Carcinoma of the Head and Neck
  • Head and Neck Squamous Cell Carcinoma
  • Oral Cavity Squamous Cell Carcinoma (Stage III)
  • Stage IVB Oral Cavity Squamous Cell Carcinoma
  • Stomach Cancer
  • HER2-negative Breast Cancer
  • Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  • Non-Small Cell Lung Cancer
  • Bladder Cancer
  • Endometrial Cancer
  • Squamous Cell Carcinoma of the Mouth
  • Oral Cavity Squamous Cell Carcinoma (Metastatic)
  • Oral Squamous Cell Carcinoma or Severe Dysplasia
  • Squamous Cell Carcinoma of the Larynx
  • Stage IV Oral Cavity Squamous Cell Carcinoma
  • Oral Squamous Cell Carcinoma
  • Cervical Cancer
  • Oral Cavity Squamous Cell Carcinoma
  • Ovarian Cancer
  • Colorectal Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Start of treatment to 30 days after last dose

Day 21
Determine the rate of dose-limiting toxicities (DLTs)
Day 30
Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

TOS-358 Single Agent Arm
1 of 1

Experimental Treatment

241 Total Participants · 1 Treatment Group

Primary Treatment: TOS-358 Single Agent Arm · No Placebo Group · Phase 1

TOS-358 Single Agent Arm
Drug
Experimental Group · 1 Intervention: TOS-358 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: start of treatment to 30 days after last dose

Who is running the clinical trial?

Totus MedicinesLead Sponsor
Ovid Trifan, MD, PhDStudy DirectorTotus Medicines

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Has the administration given its sanction to TOS-358 Single Agent Arm?

"This Phase 1 clinical trial has not accumulated substantial evidence of safety or efficacy, thus it was rated a 1 on our scale." - Anonymous Online Contributor

Unverified Answer

What is the limit of volunteers taking part in this experiment?

"Indeed, the clinicaltrials.gov page reflects that this trial is presently seeking participants. This research was initially published on February 15th 2023 and updated most recently on March 10th 2023 with a total of 241 patient enrolment at 1 site." - Anonymous Online Contributor

Unverified Answer

Are there still opportunities to partake in this investigation?

"Indeed, the information posted on clinicaltrials.gov attests that this specific medical trial is currently accepting patients. Initially advertised on February 15th 2023, it has been updated most recently in March 10th 2023." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.